RxDoctor Payments Data

Benjamin Leder, MD

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1982783924

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $47,450 of the $59,577 with a category attached, or 79.6%. Amgen accounts for 82.3% of it on its own, with 2 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,577in general payments, 2019–2025

Across 36 payments — averaging $1654.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$49K
  • Radius Health, Inc.$6K
  • E.r. Squibb & Sons, L.L.C.$4K
$864,373in research payments, 2019–2025

Across 42 payments — averaging $20,580 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$746K
  • Radius Health, Inc.$73K
  • AbbVie$45K

What the payments were for

  • Consulting fees$47,45080%
  • Speaking & faculty fees$9,09915%
  • Travel & lodging$2,5394%
  • Food & beverage$4891%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen31$49,038
Radius Health, Inc.4$6,440
E.r. Squibb & Sons, L.L.C.1$4,099

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,577 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$62,465
Medicare patients
954
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide23$92,938
ForteoTeriparatide17$83,798
TymlosAbaloparatide18$48,390
Ibandronate Sodium43$2,244
Alendronate Sodium83$625
Prednisone17$154
Levothyroxine Sodium15$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$6,440$48,39018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

Other endocrinology, diabetes & metabolism in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →